| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
One of the promising therapeutic strategies for malignancies is an oncolytic virotherapy. We have conducted a study of oncolytic herpes simplex viruses (oHSVs) against gastric cancer. In this project, we examined the antitumor effect of fourth-generation oHSVs, which contains ICP6 gene driven human TERT (telomerase reverse transcriptase) promoter (T-hTERT) and T-SOCS-3 expressing suppressor of cytokine signaling-3. For human gastric cancer cell line, we examined the expression of ribonucleotide reductase (RR) activity and their telomerase activity in gastric cancer cell line, and also evauated the cytotoxicity of T-hTERT and T-SOCS-3. T-hTERT was more effective than T-01 and T-SOCS-3 for all gastric cancer cell lines including MKN1. In addition, we are going to establish the predictive models for therapeutic efficacy using freshly surgical specimens of gastric cancer patients.
|
